STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.